Merck (NYSE:MRK) - Cotización, noticias y análisis

Resumen de acción MRK

Merck & Co., Inc. opera como empresa sanitaria en todo el mundo. Saber más

Análisis fundamental de MRK
Puntuación del snowflake
Valoración	5/6
Crecimiento futuro	3/6
Rendimiento pasado	5/6
Salud financiera	4/6
Dividendos	5/6

Recompensas

Cotiza un 65.2% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 15.58%

Los beneficios aumentaron un 163.6% el pasado año

Paga dividendo fiable de 3.16%

Los analistas coinciden en que el precio de las acciones subirá un 34.5%

Análisis de riesgos

Grandes partidas extraordinarias que afectan a los resultados financieros

Tiene un alto nivel de endeudamiento

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

Advancing New Therapies And Expanding Global Markets Pave The Way For Long-Term Growth And Innovation

Key Takeaways Expanding product pipeline and R&D investments aim to boost revenue, long-term growth, and market share in key therapeutic areas. Ongoing demand for KEYTRUDA and strategic vaccine expansion anticipate robust revenue growth and improved market presence globally.

View narrative

US$131.08

25.7% undervalued

5.59%

Revenue growth p.a.

Updated

Competidores de Merck & Co., Inc.

Johnson & Johnson

NYSE:JNJ

US$368.4b

Pfizer

NYSE:PFE

US$142.2b

Eli Lilly

NYSE:LLY

US$657.1b

Zoetis

NYSE:ZTS

US$79.2b

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Merck
Precios históricos de las acciones
Precio actual de la acción	US$97.44
Máximo en las últimas 52 semanas	US$134.63
Mínimo de 52 semanas	US$94.48
Beta	0.41
1Cambio en 1 mes	-8.37%
Variación en 3 meses	-16.40%
Cambio de 1 año	-4.17%
3Variación en 3 años	18.42%
Variación en 5 años	11.22%
Variación desde la OPV	8,561.33%

Noticias y actualizaciones recientes

The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The Business

Nov 15

Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks

Nov 14

Recent updates

The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The Business

Nov 15

Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks

Nov 14

Merck: An Undervalued Dividend Machine

Nov 07

Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda Threat

Oct 25

Rentabilidad de los accionistas

	MRK	US Pharmaceuticals	Mercado US
7D	-1.1%	-3.8%	-1.0%
1Y	-4.2%	9.8%	30.3%

Rentabilidad vs. Industria: Los resultados de MRK fueron inferiores a los de la industria US Pharmaceuticals, que obtuvo un rendimiento del 9.8% el año pasado.

Rentabilidad vs. Mercado: MRK obtuvo unos resultados inferiores a los del mercado US, que fueron del 30.3% el año pasado.

Volatilidad de los precios

Is MRK's price volatile compared to industry and market?
MRK volatility
MRK Average Weekly Movement	2.4%
Pharmaceuticals Industry Average Movement	9.6%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Precio estable de las acciones: MRK no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de MRK (2%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1891	71,000	Rob Davis	www.merck.com

Merck & Co. opera como empresa de asistencia sanitaria en todo el mundo. Opera a través de dos segmentos: Farmacéutico y Salud Animal. El segmento Farmacéutico ofrece productos farmacéuticos para la salud humana en las áreas de oncología, cuidados agudos hospitalarios, inmunología, neurociencia, virología, cardiovascular y diabetes bajo las marcas Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi y Januvia, así como productos vacunales consistentes en vacunas preventivas pediátricas, para adolescentes y adultos bajo las marcas Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23 y Vaqta.

Resumen de fundamentos de Merck & Co., Inc.

¿Cómo se comparan los beneficios e ingresos de Merck con su capitalización de mercado?
Estadísticas fundamentales de MRK
Capitalización bursátil	US$244.21b
Beneficios(TTM)	US$12.15b
Ingresos (TTM)	US$63.17b

20.3x

Ratio precio-beneficio (PE)

3.9x

Ratio precio-ventas (PS)

¿Está MRK sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de MRK
Ingresos	US$63.17b
Coste de los ingresos	US$14.79b
Beneficio bruto	US$48.39b
Otros gastos	US$36.24b
Beneficios	US$12.15b

Últimos beneficios comunicados

Sep 30, 2024

Próxima fecha de beneficios

Feb 04, 2025

Beneficios por acción (BPA)	4.80
Margen bruto	76.59%
Margen de beneficio neto	19.23%
Ratio deuda/patrimonio	85.6%

¿Cómo se ha desempeñado MRK a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

3.2%

Rentabilidad actual por dividendo

63%

Ratio de pagos

Resumen de acción MRK

Recompensas

Análisis de riesgos

Advancing New Therapies And Expanding Global Markets Pave The Way For Long-Term Growth And Innovation

Competidores de Merck & Co., Inc.

NYSE:JNJ

US$368.4b

NYSE:PFE

US$142.2b

NYSE:LLY

US$657.1b

NYSE:ZTS

US$79.2b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab with Berahyaluronidase Alfa Met Primary Endpoints

The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The Business

Merck Receives Positive EU CHMP Opinion for KEYTRUDA Plus Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Non-Epithelioid Malignant Pleural Mesothelioma

Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks

Alexion, AstraZeneca Rare Disease and Merck Announces Positive Topline Results from the Phase 3 Komet Trial

Merck Announces Canada's Drug Agency Recommends WINREVAIR (sotatercept) for Reimbursement

Recent updates

Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab with Berahyaluronidase Alfa Met Primary Endpoints

The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The Business

Merck Receives Positive EU CHMP Opinion for KEYTRUDA Plus Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Non-Epithelioid Malignant Pleural Mesothelioma

Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks

Alexion, AstraZeneca Rare Disease and Merck Announces Positive Topline Results from the Phase 3 Komet Trial

Merck Announces Canada's Drug Agency Recommends WINREVAIR (sotatercept) for Reimbursement

Merck: An Undervalued Dividend Machine

Third quarter 2024 earnings: EPS misses analyst expectations

Merck and Moderna, Inc. Initiates Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients with Certain Types of Non-Small Cell Lung Cancer (NSCLC)

CDC's ACIP Recommends Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older

Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda Threat

Merck's KEYTRUDA® (Pembrolizumab) Receives 30th Approval from European Commission with Two New Indications in Gynecologic Cancers

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Merck Announces the Presentation of Positive Results from the Phase 2B/3 Clinical Trial (Mk-1654-004) Evaluating Clesrovimab

Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease

Market Still Lacking Some Conviction On Merck & Co., Inc. (NYSE:MRK)

Merck & Co., Inc. to Report Q3, 2024 Results on Oct 31, 2024

Merck Is At Support And Should Go Higher (Technical Analysis)

FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Merck Announces Overall Survival Results from the Final Analysis of the Phase 3 Keynote-811 Trial Evaluating Keytruda® (Pembrolizumab)

Merck Appears Ready To Return To June Highs (Technical Analysis)

Upcoming dividend of US$0.77 per share

Merck Announces WINREVAIR (Sotatercept) Is Authorized for Use in Canada for Adults with Pulmonary Arterial Hypertension

Merck & Co., Inc. and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™? for the Treatment of Diabetic Macular Edema

European Commission Approves Merck's KEYTRUDA (Pembrolizumab) Plus Padcev (Enfortumab Vedotin-Ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults

Merck's Change To Profit Guidance Provides An Opportunity

Merck & Co., Inc. Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials

Merck Receives European Commission Approval for Winrevair (Sotatercept) in Combination with Other Pulmonary Arterial Hypertension (Pah) Therapies, for the Treatment of Pah in Adult Patients with Functional Class II-III

Health Canada Approves Merck's KEYTRUDA® for the Treatment of Adult Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer with No Prior Systemic Therapy for mUC, in Combination with Enfortumab Vedotin

Merck: Buy This Bargain Before It's Gone

Merck & Co., Inc. Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Merck & Co., Inc.

20.3x

3.9x

Beneficios e Ingresos

Dividendos

3.2%

63%